A research team led by Prof. Liu Qingsong from the Hefei Institutes of Physical Science of the Chinese Academy of Science has ...

During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...

The FDA had earlier accepted CYTK’s new drug application (NDA) for lead pipeline candidate aficamten and assigned a standard review to the candidate with a target action date of Sept. 26, 2025.

Cytokinetics, Incorporated announced that the FDA has extended the action date for aficamten, a treatment for obstructive hypertrophic cardiomyopathy (oHCM), to December 26, 2025. The extension is ...

Potential Positives Positive guidance on the PDUFA target action date for aficamten, set for September 26, 2025, indicating potential near-term revenue opportunities.

Furthermore, cytokines can exhibit synergistic effects, where one cytokine enhances the activity of another, or antagonistic effects, where one cytokine inhibits the action of another. This complex ...

Cytokine release syndrome (CRS) is a condition caused by certain medications, treatments, and infections. It happens when a large volume of proteins known as cytokines are suddenly released into the ...

A more advanced form of IL-2 cytokine therapy called IL-2 smart cytokines could overcome side effects, and shake up cancer care.

Synthekine is partnering with Sanofi to develop and commercialize IL-10 receptor agonist therapies for inflammatory diseases, through a collaboration that will pay Synthekine at least $40 million ...